Review article: Faecal markers in the assessment of activity in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 16, Issue 4, 2002, Pages 675-681

  Poullis, A ^a   Foster, R ^b   Northfield, T C ^a   Mendall, M A ^c  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; CALPROTECTIN; CHROMIUM 51; CYTOKINE; ELASTASE INHIBITOR; HEMOGLOBIN; IMMUNOGLOBULIN; INDIUM 111; LACTIC ACID; LACTOFERRIN; LYSOZYME; MYELOPEROXIDASE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

COLON BIOPSY; COLONOSCOPY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE MARKER; ENTERITIS; ERYTHROCYTE; FECES ANALYSIS; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; INTESTINE LAVAGE; INTESTINE TUMOR; ISOTOPE LABELING; LABORATORY TEST; LEUKOCYTE; NEUTROPHIL; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; QUESTIONNAIRE; RELIABILITY; REVIEW; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; FECES; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 0036113795     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2002.01196.x     Document Type: Review

References (47)

1. Review article: Quantitative leucocyte scanning in the assessment of inflammatory bowel disease activity and its response to therapy
2. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases
3. Laboratory tests and activity indices in acute ulcerative colitis with respect to the extent of the disease
4. Inflammatory bowel disease and irritable bowel syndrome
5. Sulfasalazine vs. steroids in Crohn's disease: David vs. Goliath?
6. Clinical investigation of gut immune responses. Review of non-parenteral vaccines
7. Gut lavage fluid protein concentrations: Objective measures of disease activity in inflammatory bowel disease
8. Gut mucosal secretion of interleukin 1 beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease
9. Investigation of neutrophils in the gut lumen by assay of granulocyte elastase in whole-gut lavage fluid
10. 111Indium autologous granulocytes in the detection of inflammatory bowel disease
11. 111-granulocyte excretion
12. Indium-111-labelled autologous leukocyte imaging and faecal excretion. Comparison of conventional methods of assessment of inflammatory bowel disease
13. 111-labelled leucocyte excretion in the assessment of disease in Crohn's disease
14. 111Indium autologous leucocytes in inflammatory bowel disease
15. Significance of faecal lysozme excretion and alph-1-antitrypsin clearance in the assessment of activity of inflammatory bowel disease
16. Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel
17. 3) proteins in patients with Crohn's disease
18. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis
19. Determination of fecal alpha 1-antitrypsin concentration by radial immunodiffusion: Two systems compared
20. Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease
21. Evaluation of ulcerative colitis and Crohn's disease activity by measurement of alpha-1-antitrypsin intestinal clearance
22. Serumorosomucoid in ulcerative colitis. Its relation to clinical activity, protein loss, and turnover of albumin and IgG
23. Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases
24. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease
25. Faecal excretion of alpha 2-macroglobulin: A novel marker for disease activity in patients with inflammatory bowel disease
26. Cortisone in ulcerative colitis. Final report on a therapeutic trial
27. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis
28. Intestinal protein loss and bleeding assessed by fecal hemoglobin, transferrin, albumin, and alpha-1-antitrypsin levels in patients with colorectal diseases
29. Increased proteolysis and leucine aminopeptidase activity in faeces of patients with Crohn's disease
30. Serum and faecal lysozyme in inflammatory bowel disease
31. Faecal lactoferrin as a marker of disease activity in inflammatory bowel disease: Comparison with other neutrophil derived proteins
32. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease
33. Differential excretion of leucocyte granule components in inflammatory bowel disease: Implications for pathogenesis
34. Faecal elastase reflects disease activity in active ulcerative colitis
35. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
36. Tumour necrosis factor/cachectin in Crohn's disease. Relation of serum concentration to disease activity
37. Calprotectin (the L1 leukocyte protein)
38. Functional and clinical aspects of the myelomonocytic protein calprotectin
39. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study
40. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease
41. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein
42. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease
43. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea reffered for colonoscopy
44. Fecal anions and lactate in severe ulcerative colitis
45. Faecal DL-lactate concentration in 100 gastrointestinal patients
46. Platelet activating factor in stool from patients with ulcerative colitis and Crohn's disease
47. Detection of pro and inflammatory cytokines in stools of patients with inflammatory bowel disease